Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.60 |
| ▸ | FLT1 | P17948 | 6/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015469 | 0.96 | KDR (0.57) | KDRFLT1FGFR1PDE10ASRC | |
| SCHEMBL5245231 | 0.87 | PDE10A (0.56) | KDRFLT1FGFR1PDE10ACYP1A2 | |
| SCHEMBL29589019 | 0.87 | PDE10A (0.56) | KDRFLT1FGFR1PDE10ACYP1A2 | |
| Hydrochloric Acid SCHEMBL6097190 | 0.85 | PDE10A (0.55) | KDRFLT1FGFR1PDE10ACYP1A2 | |
| SCHEMBL3461866 | 0.85 | KDR (0.46) | KDRFLT1FGFR1PDE10ASRC | |
| SCHEMBL4772499 | 0.83 | KDR (0.54) | KDRFLT1FGFR1PDE10ASRC | |
| SCHEMBL4775174 | 0.83 | FLT1 (0.60) | KDRFLT1FGFR1PDE10APDPK1 | |
| SCHEMBL6098070 | 0.83 | FLT1 (0.60) | KDRFLT1FGFR1PDE10APDPK1 | |
| SCHEMBL5025550 | 0.80 | EHMT2 (0.58) | KDRFLT1FGFR1SRCFLT4 | |
| Hydrochloric Acid SCHEMBL6096022 | 0.80 | EHMT2 (0.57) | KDRFLT1FGFR1SRCFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | KDR 13/4885FLT1 5/4885FGFR1 559/4885 |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KDR 50/4885FLT1 17/4885FGFR1 147/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KDR 50/4885FLT1 17/4885FGFR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.